Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents.

Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T.

Rheumatology (Oxford). 2010 Jul;49(7):1215-28. doi: 10.1093/rheumatology/keq031. Epub 2010 Mar 1. Review.

2.

Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab.

Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, To K, Harashima S, Hatta N, Harada M.

Arthritis Rheum. 2008 May;58(5):1248-57. doi: 10.1002/art.23447.

3.

Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha.

Mitoma H, Horiuchi T, Hatta N, Tsukamoto H, Harashima S, Kikuchi Y, Otsuka J, Okamura S, Fujita S, Harada M.

Gastroenterology. 2005 Feb;128(2):376-92.

PMID:
15685549
4.

The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α.

Ueda N, Tsukamoto H, Mitoma H, Ayano M, Tanaka A, Ohta S, Inoue Y, Arinobu Y, Niiro H, Akashi K, Horiuchi T.

Inflamm Bowel Dis. 2013 May;19(6):1224-31. doi: 10.1097/MIB.0b013e318280b169.

PMID:
23619715
5.

Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor.

Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, Salfeld J, Sasso EH.

Clin Immunol. 2009 May;131(2):308-16. doi: 10.1016/j.clim.2009.01.002. Epub 2009 Feb 1.

PMID:
19188093
6.

Tumor necrosis factors blocking agents: analogies and differences.

Benucci M, Saviola G, Manfredi M, Sarzi-Puttini P, Atzeni F.

Acta Biomed. 2012 Apr;83(1):72-80. Review.

PMID:
22978063
7.

Binding and functional comparisons of two types of tumor necrosis factor antagonists.

Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C.

J Pharmacol Exp Ther. 2002 May;301(2):418-26.

8.

Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages.

Atreya R, Zimmer M, Bartsch B, Waldner MJ, Atreya I, Neumann H, Hildner K, Hoffman A, Kiesslich R, Rink AD, Rau TT, Rose-John S, Kessler H, Schmidt J, Neurath MF.

Gastroenterology. 2011 Dec;141(6):2026-38. doi: 10.1053/j.gastro.2011.08.032. Epub 2011 Aug 27.

PMID:
21875498
9.

Anti-tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner.

Vos AC, Wildenberg ME, Duijvestein M, Verhaar AP, van den Brink GR, Hommes DW.

Gastroenterology. 2011 Jan;140(1):221-30. doi: 10.1053/j.gastro.2010.10.008. Epub 2010 Oct 16.

PMID:
20955706
10.

Tumor necrosis factor inhibitors block apoptosis of human epithelial cells of the salivary glands.

Sisto M, D'Amore M, Caprio S, Mitolo V, Scagliusi P, Lisi S.

Ann N Y Acad Sci. 2009 Aug;1171:407-14. doi: 10.1111/j.1749-6632.2009.04688.x.

PMID:
19723083
11.
12.

TNF blocker drugs modulate human TNF-α-converting enzyme pro-domain shedding induced by autoantibodies.

Sisto M, Lisi S, Lofrumento DD, Caprio S, Mitolo V, D'Amore M.

Immunobiology. 2010 Nov;215(11):874-83. doi: 10.1016/j.imbio.2009.11.005. Epub 2009 Dec 29.

PMID:
20061048
13.

Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody.

Solau-Gervais E, Laxenaire N, Cortet B, Dubucquoi S, Duquesnoy B, Flipo RM.

Rheumatology (Oxford). 2006 Sep;45(9):1121-4. Epub 2006 Mar 1.

14.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

15.
16.

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.

Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP.

Pharmacol Ther. 2008 Feb;117(2):244-79. Epub 2007 Oct 26. Review.

PMID:
18155297
17.

Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.

Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, Brown D, Robinson M, Bourne T.

Inflamm Bowel Dis. 2007 Nov;13(11):1323-32.

PMID:
17636564
19.

Reactivation of latent granulomatous infections by infliximab.

Wallis RS, Broder M, Wong J, Lee A, Hoq L.

Clin Infect Dis. 2005 Aug 1;41 Suppl 3:S194-8.

20.

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.

Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJ.

Gastroenterology. 2003 Jun;124(7):1774-85.

PMID:
12806611
Items per page

Supplemental Content

Write to the Help Desk